No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 16 of the 32 quarters in the window, leaving 16 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 75.7x · 10Y median 18.6x · 95th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 33
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T16:27:25.338Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Korsana Biosciences, Inc. (KRSA) stock was $30.73 as of Oct 6, 2026, 12:25 PM EDT, up 0.02% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +75.1% · 3-year avg +11.6%/yr · 5-year avg -40.4%/yr
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics.
Biotechnology · Waltham, MA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2024-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 11, 2026
36 days away
EPS Estimate
-0.92
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.41
vs Estimate
$-3.45
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1KRSA | $143.85M | $30.73 | +0.02% | +75.07% | -40.41% | N/A | N/A |
| 2IMRX | $143.94M | $3.96 | -1.86% | -33.09% | -32.77% | N/A | vs KRSA |
| 3NYXH | $144.10M | $1.44 | +2.13% | -71.34% | -45.84% | N/A | vs KRSA |
| 4LFMDP | $145.38M | $21.32 | -6.74% | +6.17% | +10.80% | N/A | vs KRSA |
| 5ACOG | $140.71M | $9.06 | -0.98% | +22.21% | N/A | N/A | vs KRSA |
| 6NGEN | $147.95M | $1.80 | -0.55% | N/A | N/A | N/A | vs KRSA |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 4 analysts
Average Price Target
$44.00
+43.2% upside
Low
$8.00
Current
$30.73
High
$70.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.92 | $-0.92 | $-0.92 | 1 |
| Quarter ending Dec 2026 | $-1.01 | $-1.01 | $-1.01 | 1 |
| Quarter ending Mar 2027 | $-0.84 | $-0.84 | $-0.84 | 1 |
| Quarter ending Jun 2027 | $-0.88 | $-0.88 | $-0.88 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-3.27 | $-3.27 | $-3.27 | 2 |
| FY 2027 | $-3.58 | $-3.58 | $-3.58 | 2 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $1.50M | $1.50M | $1.50M | 1 |
| Quarter ending Jun 2027 | $900000.00 | $900000.00 | $900000.00 | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $1.10M | $1.10M | $1.10M | 4 |
| FY 2027 | $586141.00 | $586141.00 | $586141.00 | 4 |
